Sobered by mounting costs, Dynavax looks to unload I/O, slash jobs and circle wagons around Heplisav
Hep B vaccine maker Dynavax has realized it needs portion control because there’s far too much on its plate.
On Thursday, the California-based company said it needed to focus all its resources on its 2017-approved Heplisav-B and its broader vaccine business, so it is exploring strategic alternatives for its immuno-oncology programs and cutting jobs.
Basic subscription required
Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.